Cytomegalovirus (CMV) infection is a major Herpes virus infection, which is the leading cause of morbidity and mortality worldwide among congenitally infected newborns, HIV/AIDS patients and transplant recipients. According to Centers for Disease Control and Prevention, approximately 80,000 cases of CMV infections are found in United States and Europe. High prevalence of Cytomegalovirus (CMV) infection is found in developing countries and in areas of lower socioeconomic conditions.
In terms of treatment scenario, several drugs such as Valganciclovir (Valcyte), Foscarnet (Foscavir), Cidofovir (Vistide) are approved and marketed. Valtrex and Cytotect are approved for Cytomegalovirus (CMV) infection, and Valganciclovir or Ganciclovir are used as first-line treatment. Additionally, Foscavir is used as second-line therapy for patients who do not respond to Ganciclovir treatment. Lastly, Cidofovir is used as an alternative therapy among those patients who do not respond to Ganciclovir and Foscarnet treatment. The current market of CMV infection is weak due to presence of several generics, such as Ganciclovir and Foscarnet, and patent expiry of marketed drugs.
Due to increasing awareness related to herpes virus infections, improvement in healthcare infrastructure, increase in number of patients undergoing transplantation, government support and increase in prevalence of CMV infection, there is a hope for the Global market size of CMV infection to increase from USD 698.3 Million in 2013 to USD 1,210.4 Million by end of year 2023. Prophylactic and therapeutic market size is expected to grow at a CAGR of 6.57% and 3.44% respectively, during 2013-2023. Major players such as Merck & Co., Chimerix Inc, Astellas Pharma and CSL Behring are developing drugs which are expected to be launched in coming years. These emerging therapies have better efficacy and safety profiles as compared to the existing therapies. Launch of emerging therapies such as Letermovir and TransVax in coming years may also stimulate growth of the CMV market. Also, companies are focusing on developing drugs with novel mechanisms of action beyond DNA polymerase inhibitors, which may provide a stiff competition to the existing therapies.